Skip to main content
. 2022 May 30;127(5):811–823. doi: 10.1038/s41416-022-01834-2

Fig. 6. PFKFB3 promotes the CXCL8 expression by activating the phosphorylation of ERBB2 S1151/PI3K/AKT/ NFκB p65 signal axis.

Fig. 6

a, b The transcription and secretion level of CXCL8 was analysed by RT-PCR and ELISA assays after transfected with PFKFB3 and S1151A plasmid. c The expression of indicated proteins in TRs transfected by recombinant WT or phosphorylation-deficient ERBB2 S1151 (ERBB2 S1151A) or the phosphorylation-mimic ERBB2 S1151 (ERBB2 S1151D) mutant. d Effect of OSU-T315, inhibition of PI3K/AKT, in cells transfected with WT or ERBB2 S1151D. e Effect of PFKFB3 knockdown or WT or ERBB2 1151D on protein expression in diverse WTs. Data are shown as fold enrichment relative to input, *P < 0.5, mean ± SEM (n = 3), based on Student’s t test. f Photographic images of PDX models (n = 3/group) bearing tissues from HER2+ patients treated with PBS/Control-AAV, trastuzumab/PFKFB3-AAV, PBS/PFKFB3-AAV or trastuzumab/PFKFB3-AAV for 8 weeks (upper). Tumour volume of PDX models at sacrifice (lower). g IF images and comparisons of VE-cadherin distribution, collagen type IV + basement membrane (BM) coverage and αSMA + pericyte coverage were presented as a percentage of length that lied along the CD31 + vascular endothelium in subcutaneously tumours. Scale bar, 50 μm.